INVIVYD, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
INVIVYD, INC. (IVVD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- INVIVYD, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.90M, a 8.96% decline year-over-year.
- INVIVYD, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.70M, a 4.56% decline year-over-year.
- INVIVYD, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.07M, a 2.13% decline year-over-year.
- INVIVYD, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.18M, a 65.16% decline year-over-year.
- INVIVYD, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $11.64M, a 42.61% decline from fiscal 2024.
- INVIVYD, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $20.29M, a 8.58% increase from fiscal 2023.
- INVIVYD, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $18.68M, a 13.69% decline from fiscal 2022.
- INVIVYD, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $21.65M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 7 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.90M 10-Q · filed 2026-08-13 | $5.59M derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $2.70M 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | $11.64M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $3.07M 10-Q · filed 2025-11-06 | $6.25M derived: sum of 2 quarters · filed 2026-08-13 | $9.08M derived: sum of 3 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $3.18M 10-Q · filed 2026-08-13 | $6.01M derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $2.83M 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | $20.29M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $3.14M 10-Q · filed 2025-11-06 | $12.27M derived: sum of 2 quarters · filed 2025-11-06 | $17.65M derived: sum of 3 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $9.13M 10-Q · filed 2025-11-06 | $14.51M derived: sum of 2 quarters · filed 2025-11-06 | |||
| 2024-03-31 | $5.38M 10-Q · filed 2025-11-06 | ||||
| 2023-12-31 | $18.68M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $4.26M 10-Q · filed 2024-11-14 | $8.94M derived: sum of 2 quarters · filed 2024-11-14 | $14.34M derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $4.68M 10-Q · filed 2024-11-14 | $10.08M derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | $5.40M 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $21.65M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $7.40M 10-Q · filed 2023-11-09 | $13.76M derived: sum of 2 quarters · filed 2023-11-09 | $15.74M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $6.36M 10-Q · filed 2023-11-09 | $8.34M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $1.98M 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $17.76M 8-K · filed 2024-02-09 | ||||
| 2021-09-30 | $5.98M 10-Q · filed 2022-11-10 | $9.32M derived: sum of 2 quarters · filed 2022-11-10 | $9.91M derived: sum of 3 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $3.34M 10-Q · filed 2022-11-10 | $3.93M derived: sum of 2 quarters · filed 2022-11-10 | |||
| 2021-03-31 | $587.00K 10-Q · filed 2022-11-10 | ||||
| 2020-12-31 | $155.00K 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $7.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |